Navigation Links
New Critical Path Report Highlights Research Needed to Foster,Generic Drug Development

ROCKVILLE, Md., May 2, 2007-The U.S. Food and Drug Administration (FDA) today issued the "Critical Path Opportunities for Generic Drugs" report identifying many of the unanswered scientific questions that impede the development of generic versions of commonly used drugs.

The report is part of FDA's Critical Path Initiative, established in 2004 to discern what challenges exist in moving a promising drug, biologic or device along the critical path from discovery, or proof of concept, to a marketable product. Solving these challenges will require the expertise and input of many groups, including scientists from universities, patient groups, government, industry, associations and other private organizations.

"This report pinpoints the barriers that are limiting the availability of additional generic drug options," said Gary Buehler, R.Ph., director, FDA's Office of Generic Drugs. "We hope these findings will encourage research collaboration, lower these barriers and accelerate access to safe and effective generic drugs."

Before they can be approved, generic drugs must have the same active ingredient, dosage form, strength, and conditions of use as the brand name drug. The drugs must also be absorbed at the same rate and in the same amount, a concept known as bioequivalence.

While straightforward tests of blood plasma levels are sufficient to demonstrate bioequivalence for most generic drug candidates, these common tests generally are not appropriate for certain drugs, including asthma inhalers, nasal sprays, and topical skin applications such as anti-fungal creams. As a result, few generic versions are available in these product categories, resulting in less competition and higher prices.

For example, generic drug products that contain the ozone-depleting substance chlorofluorocarbon will be withdrawn from the market after 2008. The new report will help ensure FDA has an adequate scientific basis to review inhaler applications that use an alternative, hydrofluoroalkane.

The report also calls for research on new bioequivalence methods tailor-made for each challenging drug class. These include lung function tests and molecular level imaging for inhalation drugs; particle size distribution tests for nasal sprays; and methods for direct measurement of drug delivered to the skin.

In addition, the report highlights possible research projects that might lead to new modeling and simulation tools for drug absorption, drug release and other drug development issues and to alternative methods for seeking waivers from clinical bioequivalence studies.

Last year FDA issued the Critical Path Opportunities Report listing 76 specific scientific projects that, if undertaken, would help modernize the Critical Path sciences. This companion document focuses more narrowly on the scientific challenges unique to the development of generic drugs.

To learn more about the Critical Path Initiative consult:
www.fda.gov/oc/initiatives/criticalpath/

Information on FDA's Generic Drug Office is available at:
www.fda.gov/cder/ogd/index.htm.

####

Media Inquiries:
Karen Riley, 301-827-6242
Consumer Inquiries:
888-INFO-FDA


'"/>




Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
3. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
4. Critical Therapeutics Announces the Publication of New Preclincial HMGB1 Data in Nature Immunology
5. Data Show SuperGens Multi-Targeted Tyrosine Kinase Inhibitor Suppresses Critical Double-Stranded DNA Repair Protein, Rad51
6. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
9. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... --  The Harrington Discovery Institute at University ... has announced the 2017 recipients of Harrington Scholar-Innovator ... whose research shows promise to advance the standard ... – part of The Harrington Project for Discovery ... medicine: to advance early breakthroughs into the clinical ...
(Date:1/16/2017)... , January 16, 2017 According to the ... Controller, Multi Display , Smart Display, Graphic LCD Controller), Application (Industrial ... 2022", published by MarketsandMakets, the market is expected to grow from USD ... a CAGR of 9.68% between 2016 and 2022. ... ...
(Date:1/16/2017)... 16, 2017 The ... Type (Methyl, Ethyl, Hydroxyethyl, Hydroxypropyl, Carboxymethyl Cellulose), ... Surface Coatings & Paints), Region - Global ... market was valued at USD 4.51 Billion ... USD 6.41 Billion by 2021, at a ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... 2017 , ... Permobil has just completed the acquisition of ... systems has a well-earned reputation for premium quality, with a focus on fit ... in the custom seating business, which enjoys strong demand, and it complements Permobil’s ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... ... announce their recent partnership with an innovator in the wheelchair accessibility industry, ... motivate their dealer salespeople to sell wheelchair accessible vehicles. With this new incentive ...
(Date:1/16/2017)... ... January 16, 2017 , ... Date aired: January 9, 2017 ... Sharon Kleyne, America’s leading water educator, researcher and advocate welcomed health activist, author, ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health on ...
(Date:1/16/2017)... ... January 16, 2017 , ... In ... education and high-level training standards to an international multidisciplinary group of healthcare treatment ... As a way to further its mission at the grassroots level, iaedp launched ...
(Date:1/16/2017)... ... 16, 2017 , ... San Francisco dentist, Dr. Ben Amini , the ... device which is capable of taking digital impressions of teeth and gums. Conventional bite ... CAD CAM restorations , in terms of speed, efficiency and patient comfort. Increasingly, digital ...
Breaking Medicine News(10 mins):